Overview of Sales, Earnings and Financial Position
Bayer Links
News
Phase III study program on rivaroxaban in chronic indications
After extensive discussions with the regulatory authorities in the U.S. and Europe, Bayer and Ortho-McNeil, Inc. have determined the final design of the phase III study program for the oral anticoagulant rivaroxaban in two chronic indications. » more
After extensive discussions with the regulatory authorities in the U.S. and Europe, Bayer and Ortho-McNeil, Inc. have determined the final design of the phase III study program for the oral anticoagulant rivaroxaban in two chronic indications. » more
China is of central importance to Bayer
At a ceremony before 500 guests, Bayer inaugurated the new production facilities of the Bayer MaterialScience subgroup in Shanghai. » more
At a ceremony before 500 guests, Bayer inaugurated the new production facilities of the Bayer MaterialScience subgroup in Shanghai. » more
Schering integration well on track
Bayer is proceeding apace with the integration of Schering. In recent weeks, executive appointments in the future Bayer Schering Pharma have been made through the third management level, and three further major decisions have now also been made. » more
Bayer is proceeding apace with the integration of Schering. In recent weeks, executive appointments in the future Bayer Schering Pharma have been made through the third management level, and three further major decisions have now also been made. » more
News Overview
Bookmark this page
E-mail this page
Advanced Search
